ArticleFrontiers in pharmacology2025
Urinary urodilatin levels in patients with renal salt wasting syndrome as a possible new diagnostic marker. A pilot study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal Salt Wasting Syndrome (RSW) is a clinical syndrome with laboratory characteristics completely overlapping with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). No studies have yet investigated the potential role of urodilatin as a diagnostic marker or its involvement in the pathogenesis of RSW. Methods: We performed a retrospective observational case-control study, the patients were divided into 3 groups: a group of hyponatremic patients with RSW (cases) and two control groups (subjects without hyponatremia and subjects with hyponatremia from other causes). Main outcomes were assessing the differences in urinary urodilatin values in patients with RSW compared to both control groups and to evaluate the diagnostic power of urodilatin with the analysis of ROC curves. Results: Patients with RSW display significantly higher mean urodilatin levels than both patients with (median 5.46 vs. 0.57 ng/mL, p = 0.006) or without hyponatremia (median 5.46 vs. 0.27 ng/mL, p < 0.001). Diagnostics performances of mean urodilatin levels for RSW diagnosis were evaluated by ROC curve, AUC was 0.94 (95%CI 0.86-1.00). Conclusion: This case-control study has shown interesting results regarding the dosage of urinary urodilatin in patients with RSW, with potentially clarifying implications both regarding the pathogenesis of this syndrome and regarding the diagnosis and therefore the clinical management of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.